This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics to Buy Laboratory Services Unit in Midwest
by Zacks Equity Research
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail
by Zacks Equity Research
The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.
Align Technology's New iTero Scanner Updates to Boost Uptake
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull
by Zacks Equity Research
Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.
Here's Why You Should Invest in Merit Medical (MMSI) Now
by Zacks Equity Research
A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.
Here's Why You Should Invest in Abiomed (ABMD) Right Now
by Zacks Equity Research
Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.
RTI Surgical Gains From HealthPartners' Nod for SI Surgery
by Zacks Equity Research
RTI Surgical's (RTIX) minimally invasive SImmetry System sees lucrative market prospects for the stock's growth.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Express Scripts & Petco Tie Up, Ease Access to Pet Medicines
by Zacks Equity Research
Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.
Are WMGI & ARAY Neck and Neck? Let's Take a Closer Look
by Zacks Equity Research
Wright Medical (WMGI) scores higher than Accuray (ARAY) when it comes to current-year earnings and growth projections.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.
Medidata's Cloud Platform Picked by China's Hengrui, Stock Up
by Zacks Equity Research
Medidata's (MDSO) cloud-based platform sees immense prospects in APAC.
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.
SurModics (SRDX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 600.00% and 2.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wright Medical (WMGI) Takes Over Cartiva for $435M in Cash
by Zacks Equity Research
The Cartiva buyout will boost Wright Medical's (WMGI) Lower Extremities business.
Express Scripts Introduces Medicare PDP Offerings for 2019
by Zacks Equity Research
Express Scripts' (ESRX) Medicare PDP to initiate coverage from Jan 1, 2019. The plan includes Walmart along with CVS Pharmacy and the Kroger Family of Pharmacies.
Here's Why You Should Hold Ecolab Stock in Your Portfolio
by Zacks Equity Research
Despite fluctuations in the cost of raw materials, Ecolab (ECL) to gain from strong performance in the Global Industrial segment.
AtriCure (ATRC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
AtriCure (ATRC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
Here's Why You Should Hold Medidata Stock in Your Portfolio
by Zacks Equity Research
Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.
Buy These 4 Efficient Stocks for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.